*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Celadon Pharmaceuticals Plc is a United Kingdom-based pharmaceutical company. The Company is engaged in research, cultivation, manufacturing and supply of cannabinoid-based medicines. The Company is focused on growing indoor hydroponic cannabis initially for the chronic pain market. It is also focused on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions, such as autism and multiple sclerosis. The Company's facility comprises an indoor, closed-loop hydroponic system to ensure cannabis plants are cultivated under a highly specific climate, light and with irrigation control.
Registrars:
Key Personnel
CEO:
James Short
CFO:
Jonathan Turner
Non-Executive Chairman:
I Alexander Anton
Senior Independent Non-Executive Director:
Robert Barr
Independent Non-Executive Director:
David Firth, Liz Shanahan, Steven (Steve) Hajioff
Contact Details
Address:
32-33 Cowcross Street, London, England, United Kingdom